Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2000

View Archived Issues

Licensing opportunity from NIH: modified HCV peptide vaccine

Genentech and Aradigm commence phase II study of CF therapy

FDA accepts InKine's Diacol NDA for filing

The Medicines Company acquires bacterial vaginosis treatment from GyneLogix

Medinox's NO neutralizer blocks sepsis in rat model

Antisense oligonucleotides designed at Isis for modulating PKC expression

DuPont scientists prepare new antiplatelet fibrinogen antagonists

Ontogen achieves milestone in PTPase collaboration with Novo Nordisk

Lilly designs new series for activating the 5-ht1f receptor

Anticancer and antimetastatic integrin inhibitors in the pipeline at BioChem Pharma

Antimalarial benflumetol derivatives with improved activity disclosed by Novartis

4-Arylpiperidines as 5-HT reuptake inhibitors

Novel, highly water soluble salt of sildenafil suitable for intranasal administration

Revised labeling for Propulsid prompted by continuing reports of cardiac adverse events

Angstrom's A6 receives U.S. patent protection; company preparing to begin phase I trials

Metabolex acquires Shaman's antidiabetic drug development program

Advanced cancer stabilized by copper-lowering drug in U-M study

Biomira initiates next stage of phase II testing of BLP25/liposomal IL-2

U.S. patent issues for Ribozyme's hepatitis B virus ribozyme

PADRE technology shows promise as universal vaccine immune stimulant

Overcoming antibiotic resistance: unusually high bactericidal activity of nisin explained

Synaptic and Kissei enter genomics research collaboration

Phase III results disappointing for marimastat in pancreatic cancer

Scios discusses plans for p38 kinase inhibitors

IL-9 expression increased in asthma

EPISTENT diabetic subgroup results: abciximab + stenting associated with better outcome

Amgen files for regulatory approval of NESP and Kineret during 1999